Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 07, 2020, titled "Zydus announcesPhase I trials of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor".
Press Release Dec 07 2020
Filed with NSE ·
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 04 2020
- Press Release Nov 28 2020
- Press Release Nov 12 2020
- Press Release Nov 03 2020
- Press Release Nov 02 2020
Later from Zydus Lifesciences
- Press Release Dec 09 2020
- Press Release Dec 24 2020
- Press Release Dec 30 2020
- Press Release Jan 04 2021
- Press Release Jan 23 2021
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences